856 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 856 shares of the life sciences company’s stock, valued at approximately $315,000.

Other institutional investors also recently bought and sold shares of the company. Strategy Asset Managers LLC purchased a new stake in shares of Illumina in the 1st quarter worth approximately $26,000. C J Advisory Inc purchased a new stake in shares of Illumina in the 1st quarter worth approximately $29,000. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Illumina in the 2nd quarter worth approximately $37,000. Valeo Financial Advisors LLC grew its stake in shares of Illumina by 130.0% in the 1st quarter. Valeo Financial Advisors LLC now owns 115 shares of the life sciences company’s stock worth $36,000 after buying an additional 65 shares during the last quarter. Finally, Mizuho Securities Co. Ltd. purchased a new stake in shares of Illumina in the 1st quarter worth approximately $37,000. Institutional investors own 90.95% of the company’s stock.

Several analysts recently weighed in on the company. Deutsche Bank cut their price target on Illumina from $290.00 to $280.00 and set a “hold” rating on the stock in a research note on Friday, July 12th. Bank of America downgraded Illumina from a “buy” rating to an “underperform” rating and set a $310.00 price target on the stock. in a research note on Friday, July 12th. ValuEngine upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. UBS Group upped their price target on Illumina from $350.00 to $355.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Finally, Argus cut their target price on Illumina to $340.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $330.92.

In other news, SVP Robert P. Ragusa sold 2,230 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $293.09, for a total value of $653,590.70. Following the transaction, the senior vice president now directly owns 10,685 shares in the company, valued at approximately $3,131,666.65. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Omead Ostadan sold 1,260 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $335.03, for a total value of $422,137.80. Following the completion of the transaction, the senior vice president now owns 11,945 shares in the company, valued at $4,001,933.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,458 shares of company stock worth $16,527,618. Company insiders own 0.38% of the company’s stock.

Shares of ILMN stock traded up $0.85 on Thursday, reaching $285.92. The stock had a trading volume of 19,256 shares, compared to its average volume of 1,242,876. The firm has a market cap of $41.98 billion, a PE ratio of 50.03, a P/E/G ratio of 2.71 and a beta of 1.10. Illumina, Inc. has a 1 year low of $268.62 and a 1 year high of $380.76. The company has a debt-to-equity ratio of 0.42, a quick ratio of 6.10 and a current ratio of 6.79. The stock’s 50 day simple moving average is $321.15.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.03. The firm had revenue of $838.00 million for the quarter, compared to the consensus estimate of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period last year, the business posted $1.43 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 6.04 EPS for the current year.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

See Also: Market Timing – The Benefits and the Danger

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.